Facing a new increase in worldwide Malaria cases since 2015, a global technical strategy (GTS) has been implemented by the World Health Organization (WHO) aiming a decrease of 90% of Malaria impact by 2030.This requires the development of detection devices, very easy to use, collecting data and resistant to tropical conditions devoted to:• detect persistent undetectable parasitaemia in people without symptoms or recent history of malaria• detect the main causes of fever, whereof malaria• be a simplified control reference for other diagnostics
Facing a new increase in worldwide Malaria cases since 2015, a global strategy has been developed aiming a 90% decrease in Malaria exposure by 2030. This aim requires the development of a test devoted to detect persistant undetectable parasitaemia in people without symptoms or recent history of malaria.
Malaria pre-elimination and elimination
According to WHO: Malaria elimination is the interruption of local transmission (reduction to zero incidence of indigenous cases) of a specified malaria parasite species in a defined geographic area; continued measures are required to prevent re-establishment of transmission. WHO grants this certification when a country has proven, beyond reasonable doubt, that the chain of local transmission of all human malaria parasites has been interrupted nationwide for at least the past 3 consecutive years; and that a fully functional surveillance and response system that can prevent re-establishment of indigenous transmission is in place. Based on those requirements, the detection of circulating parasites in the whole population of an endemic country will be a cornerstone of the malaria elimination certification. There is no doubt that beyond the public health interest of such a certification, the economic and political impacts of becoming a malaria free country are huge.
Our products
Magnetrap develops Malaria detection tools for symptomatic and asymptomatic carriers considering as the heart of its activities the end users at the point-of-care.
Our solutions are based on several fields experience and a true knowledge of the needs for deseases detection. We ensure the long-term economical viability of the product and the whole value chain.
The Advisory board
Jean-Marc Philippet
An experienced Managing Director with successful background in corporate reorganisation and development
Jim Thurlow
Experienced MedTech CEO and NED with significant background in Diagnostic product development and commercialisation
Pr. Robert Sauerwein
Scientific advisor - Chair of Medical Parasitology Radbout University (NL)
Jacques-François Martin
Business advisor Founder of GAVI (Global Alliance for Vaccines and Immunization)
Dr. Joris Vandeputte
Founder President of the International Alliance for Biological Standardization
Management Team
Leo Vanvrieken MSc, Eur. Ing.
40+ years experience as VP sales and marketing within international groups (e.g. DPC) and successful in bringing R&D companies to sales & marketing companies (Ikonisys, etc.)
C.Clauss
40+ years experience as worldwide QARA executive within international groups (Baxter, Novartis, Nestlé, etc.)
PhD. Nicolas Moniotte
CTO 12+ years’ experience in R&D, with a strong focus on technical and analytical development of new and novel medical products
Peter Vandeputte
CEO & Company founder Experienced executive in international groups especially in Africa
ir. Alain Martin
COO
30+ years exp. in Executive & Project Mgt within Siemens group
Pr. Bertrand Blankert
CSO Head of the Dpt. of Pharma. Analysis UMons
